諾輝健康-B(6606.HK)漲超10% 中期營收同比暴增317%
格隆匯8月23日丨諾輝健康-B(6606.HK)盤中拉昇一度漲超10%至40.35港元,市值173億港元。公司上週五盤後公佈的財報顯示,2021年上半年實現收入4393.1萬元人民幣,同比增317%;毛利2468.9萬元,較去年同期實現了超10倍增長;毛利率56.2%,較上年同期的21.3%上升約35個百分點。值得一提的是,公司結直腸癌篩查產品常衞清在2021年上半年實現收入1420萬元人民幣,同比增長149%。上半年實現發貨量約12.15萬盒,同比增長392%。常衞清毛利率從2020年同期的33.9%增長至56.6%。此外,公司旗下國內首個居家自測FIT便潛血檢測產品噗噗管在2021年上半年實現收入2960萬元,同比增長623.7%。噗噗管毛利率從2020年同期的26.4%上升到59%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.